Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: A phase II study

International Journal of Radiation Oncology Biology Physics

Volumn 56, Issue 4, 2003, Pages 974-980

  Van Laethem, Jean Luc ^a   Demols, Anne ^a   Gay, France ^a   Closon, Marie Thérèse ^b   Collette, Maryvone ^b   Polus, Marc ^b   Houbiers, Ghislain ^c   Gastelblum, Pauline ^d   Gelin, Michel ^a   Van Houtte, Paul ^d   Closset, Jean ^a  

^a ERASME HOSPITAL   (Belgium)

^b CHU SART TILMAN   (Belgium)

^c Centre Hospitalier Du Bois de L'Abbaye   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

Author keywords

Adjuvant; Gemcitabine; Pancreatic adenocarcinoma; Radiation

Indexed keywords

DISEASE CONTROL; RADIATION; SURGERY; TOXICITY;

CONCURRENT RADIATION;

TUMORS;

GEMCITABINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; EVALUATION; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MALE; NAUSEA; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION DOSE; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 0038048218     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00164-0     Document Type: Article

References (32)

1. Technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology. 117:1999;1464-1484.
2. Nitechi S.S., Sarr M.G., Colby T.V., et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas Is it really improving? Ann Surg. 221:1995;59-66.
3. Allema J.H., Remiders M.E., Van Gulik T.M., et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer. 75:1995;2069-2076.
4. Yeo C.J., Abrams R.A., Grochow L.B., et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma; Postoperative adjuvant chemoradiation improves survival - A prospective single institution experience. Ann Surg. 226:1997;621-636.
5. Kalser M.H., Ellenberg S.S. Pancreatic cancer Adjuvant combined radiation and chemotherapy following curative resection . Arch Surg. 120:1985;899-903.
6. Klinkenbijl J.H., Jeekel J., Samouhd T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection for the cancer of the pancreas and periampullary region Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group . Ann Surg. 230:1999;776-784.
7. Sohn T.A., Yeo C.J., Cameron J.L., et al. Resected adenocarcinoma of the pancreas - 616 patients Results, outcomes and prognostic indicators . J Gastrointest Surg. 4:2000;567-579.
8. Neoptolemos J.P., Dunn J.A., Stocken D.D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer A randomised controlled trial . Lancet. 358:2001;1576-1585.
9. Abrams R.A., Lillermoe K.D., Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet. 358:2001;1565.
10. Van Rijswick R.E., Jeziorski K., Wagener T., et al. Weekly high dose 5-fluorouracil (5FU) and folinic acid (LV) in metastatic pancreatic carcinoma A phase II study of the EORTC GITCCG [Abstract] . Proc Am Soc Clin Oncol. 19:2000;258a.
11. Rougier P, Ducreux M, Douillard JY, et al. Efficacy of 5FU+ cisplatin (FUP) compared to bolus 5FU in advanced pancreatic carcinoma: A randomized trial from the French Anticancer Centers Digestive group (FNLCCDG) [Abstract]. Proc Am Soc Clin Oncol 1999;18:274a.
12. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and in clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer A randomized trial . J Clin Oncol. 15:1997;2403-2413.
13. Lawrence T.S., Change E.Y., Hohn T.M., et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 34:1996;867-872.
14. Milas L., Fujii T., Hunter N., et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 59:1999;107-114.
15. McGinn C.J., Smith D.C., Szarka C.E., et al. A phase II study of gemcitabine (GEM) in combination with radiation therapy in patients with localized unresectable pancreatic cancer. [Abstract] Proc Am Soc Clin Oncol. 17:1998;264a.
16. Kudrimati M., Regine W., John W., et al. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy A phase I/II study . Proc Am Soc Clin Oncol. 18:1999;A928.
17. Epelbaum R., Rosenblatt E., Nasrallah S., et al. A phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. Proc Am Soc Clin Oncol. 19:2000;A1029.
18. Mustacchi G., Beorchia A., Milani S., et al. Gemcitabine and concomitant radiation for locally advanced or relapsed pancreatic cancer. Proc Am Clin Oncol. 20:2001;A2288.
19. Blackstock A.W., Bernard S.A., Richards F., et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 17:1999;2208-2212.
20. Blackstock W.A., Tempero M.A., Niedwiecki D., et al. Cancer and leukemia Group B 89805 Phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma . Proc Am Soc Clin Oncol. 20:2001;A627.
21. Wolff R.A., Evans D.B., Gravel D.M., et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Proc Am Soc Clin Oncol. 17:1998;A1091.
22. Hoffman J.P., McGinn C.J., Szarka C.E., et al. A phase I study of preoperative gemcitabine with radiation therapy followed by postoperative gemcitabine for patients with localized, resectable pancreatic adenocarcinoma. Proc Am soc Clin Oncol. 17:1998;283a.
23. Wolff R.A., Evans D.B., Crane C.H., et al. Initial results of preoperative gemcitabine (GEM)-based chemoradiation for resectable pancreatic adenocarcinoma. [Abstract] Proc Am Soc Clin Oncol. 21:2002;130a.
24. Kachnic L.A., Mornex F., Partensky C., et al. Phase II trial of twice-weekly gemcitabine and concurrent radiation for the treatment of resected pancreatic cancer. Proc Am Soc Clin Oncol. 20:2001;A2334.
25. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 19:2001;4202-4208.
26. Mehta V.K., Fisher G.A., Ford J.M., et al. Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys. 48:2000;1483-1487.
27. Spitz F.R., Abruzzese J.L., Lee J.E., et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 15:1997;928-937.
28. Crane C.H., Abbruzzese J.L., Evans D.B., et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys. 52:2002;1293-1302.
29. Boven E., Schippe H., Erkelens C.A., et al. The influence of schedule and the dose of gemcitabine on the antitumor efficacy in experimental human cancer. Br J Cancer. 68:1993;52-56.
30. Ghandi V., Plunkett W. Modulatory activity of 2′2 difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 50:1990;3675-3680.
31. Shewach D., Du M. Apparent substrate inhibition of deoxycytidine kinase. [Abstract] Proc Am Assoc Cancer Res. 35:1994;425a.
32. Cervantes L., Mitry E., Lièvre A., et al. Low-dose gemcitabine for advanced non resectable pancreatic and biliary tract cancer. [Abstract] Tumori. 1:2002;S38.